We are proud to share that the TAUTEM study, which utilised Xolomon’s electronic data capture (EDC) platform, has been published in JAMA Surgery, one of the most prestigious surgical journals worldwide, with an impact factor of 15.9.
Led by Dr Xavier Serra-Aracil and his team, this multicentre, randomised clinical trial explored an alternative approach to rectal cancer treatment. The study compared chemoradiotherapy followed by transanal endoscopic microsurgery (CRT-TEM) with total mesorectal excision (TME) in patients with T2–T3ab, N0, M0 rectal cancer. The results support CRT-TEM as a less invasive yet oncologically sound option, potentially improving post-treatment quality of life.
Xolomon’s role in this important research was to provide a robust, compliant and user-friendly EDC system that allowed seamless data collection and management across multiple sites. Our technology contributed to ensuring data quality, protocol adherence and regulatory compliance—key factors for high-impact clinical publications.
We extend our sincere congratulations to the entire TAUTEM research team and especially to Dr Serra-Aracil for this outstanding achievement. At Xolomon, we are proud to support research that sets new standards in clinical practice and contributes to more accessible and effective healthcare.
🔗 You can read the full article published in JAMA Surgery here: https://jamanetwork.com/journals/jamasurgery/fullarticle/2834596?guestAccessKey=530fda36-9f73-47c5-8975-41194d226359&utm_source=jps&utm_medium=email&utm_campaign=author_alert-jamanetwork&utm_content=author-author_engagement&utm_term=1m
